PRECIGEN, INC. PGEN
We are a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients. We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
We believe that our array of technology platforms uniquely positions us among other biotechnology companies to advance precision medicine. Precision medicine is the practice of therapeutic product development that takes into account specific genetic variations within populations impacted by a disease to design targeted therapies to improve outcomes for a disease or patient population. Our proprietary and complementary technology platforms provide a strong foundation to realize the core promise of precision medicine by supporting our efforts to construct powerful gene programs to drive efficacy, deliver these programs through viral, non-viral, and microbe-based approaches to drive lower costs, and control gene expression to drive safety. Our therapeutic platforms, including AdenoVerse immunotherapy, and UltraCAR-T, are designed to allow us to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. We have developed a proprietary electroporation device, UltraPorator, designed to further streamline and ensure the rapid and cost-effective manufacturing of UltraCAR-T therapies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.7M | $3.9M | $6.2M | $26.9M | $14.3M | $32.0M | $90.7M | $151.2M | $219.5M | $190.9M |
| Cost of revenue | — | — | — | — | — | — | — | — | $29.5M | $23.9M |
| Gross profit | — | — | — | — | — | — | — | — | $189.9M | $167.0M |
| R&D | $41.3M | $53.1M | $48.6M | — | — | — | — | $404.6M | $143.2M | $112.1M |
| SG&A | $70.1M | $41.3M | $40.4M | — | — | — | — | $137.8M | $146.1M | $142.3M |
| Total operating expenses | $120.2M | $139.0M | $106.0M | — | — | — | — | $666.2M | $368.9M | $316.1M |
| Operating income | -$110.5M | -$135.0M | -$99.8M | — | — | — | — | -$505.6M | -$137.9M | -$125.2M |
| Interest expense | $3.9M | $6.0K | $468.0K | — | — | — | — | $8.5M | $611.0K | $861.0K |
| Pre-tax income | -$250.6M | -$128.0M | -$96.4M | -$80.0M | -$111.0M | -$104.5M | -$171.3M | -$395.9M | -$78.4M | -$194.2M |
| Income tax | $3.0K | $1.8M | $458.0K | $189.0K | $160.0K | $82.0K | $930.0K | $15.4M | $2.1M | $3.9M |
| Net income | -$250.6M | -$126.2M | -$95.9M | $28.3M | -$92.2M | -$170.5M | -$322.3M | -$509.3M | -$117.0M | -$186.6M |
| EPS, basic | -1.37 | -0.47 | -0.39 | 0.14 | -0.47 | -1.02 | -2.09 | — | — | — |
| EPS, diluted | -1.37 | -0.47 | -0.39 | 0.14 | -0.47 | -1.02 | -2.09 | -3.93 | -0.98 | -1.58 |
| Shares, diluted (wtd. avg.) | 313.0M | 267.7M | 244.5M | 200.4M | 197.8M | 167.1M | 154.1M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $30.2M | $29.5M | $7.8M | $48.6M | $43.3M | $52.2M | $68.4M | $110.2M | $75.5M | $69.6M |
| Short-term investments | $67.6M | $68.4M | $55.3M | $51.1M | $72.2M | $48.3M | $9.3M | $119.6M | $6.3M | $174.6M |
| Receivables | $3.9M | $926.0K | $902.0K | $978.0K | $1.3M | $16.5M | $20.6M | $21.2M | $19.8M | $21.6M |
| Total current assets | $115.2M | $102.4M | $68.8M | $118.2M | $156.6M | $148.9M | $234.6M | $285.5M | $154.0M | $315.2M |
| Property, plant and equipment | $13.8M | $13.8M | $7.1M | $7.3M | $8.6M | $34.9M | $44.0M | $86.9M | $112.7M | $64.7M |
| Goodwill | $15.2M | $19.1M | $26.6M | $36.9M | $37.6M | $54.4M | $54.1M | $93.6M | $93.8M | $157.2M |
| Other intangibles | $3.2M | $4.5M | $40.7M | $44.5M | $52.3M | $65.4M | $68.3M | $89.0M | $232.9M | $225.6M |
| Total assets | $155.5M | $145.3M | $151.0M | $216.0M | $359.9M | $314.6M | $455.8M | $716.2M | $846.9M | $949.1M |
| Accounts payable | $12.0M | $3.5M | $1.7M | $4.1M | $3.1M | $4.6M | $5.5M | $12.0M | $8.7M | $8.5M |
| Short-term debt | — | — | $0 | $43.2M | $52.0K | $360.0K | $31.7M | $479.0K | $502.0K | $386.0K |
| Total current liabilities | $37.3M | $21.5M | $23.0M | $78.6M | $34.6M | $42.1M | $122.9M | $61.6M | $80.2M | $94.6M |
| Long-term debt | $93.2M | $0 | — | $0 | $179.9M | $171.5M | $186.3M | $211.2M | $7.5M | $7.6M |
| Total liabilities | $134.6M | $78.5M | $32.5M | $89.7M | $252.5M | $247.4M | $384.1M | $337.5M | $300.3M | $379.8M |
| Retained earnings | -$2.34B | -$2.09B | -$1.96B | -$1.87B | -$1.92B | -$1.82B | -$1.65B | -$1.33B | -$847.8M | -$729.3M |
| Total equity | $20.9M | $38.5M | $118.5M | $126.3M | $107.3M | $67.2M | $71.7M | $378.7M | $546.5M | $569.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$87.8M | -$68.2M | -$66.9M | -$65.0M | -$55.8M | -$77.0M | -$135.9M | -$124.2M | -$103.7M | -$49.0M |
| Depreciation and amortisation | $3.2M | $4.5M | $6.7M | $10.8M | $13.8M | $17.5M | $24.9M | $33.1M | $31.1M | $24.6M |
| Stock-based compensation | $10.9M | $9.5M | $9.9M | $10.2M | $13.9M | $18.4M | $18.9M | $36.3M | $41.6M | $42.2M |
| Capital expenditure | $2.0M | $8.6M | $1.5M | $4.9M | $7.2M | $7.5M | $37.9M | $41.6M | $46.7M | $31.6M |
| Investing cash flow | -$1.5M | -$20.7M | -$3.1M | $226.4M | -$74.5M | $27.8M | $86.9M | -$151.2M | $104.3M | -$28.4M |
| Financing cash flow | $90.0M | $110.6M | $29.6M | -$155.3M | $121.2M | $32.7M | $8.1M | $309.8M | $4.3M | $12.1M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-018214.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $190.9M | $219.5M | $151.2M | $90.7M | $32.0M | $14.3M | $26.9M | $6.2M | $3.9M | $9.7M |
| Gross profit | $167.0M | $189.9M | — | — | — | — | — | — | — | — |
| Net income | -$186.6M | -$117.0M | -$509.3M | -$322.3M | -$170.5M | -$92.2M | $28.3M | -$95.9M | -$126.2M | -$250.6M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |